Publications by authors named "Gary Polwarth"
Background: We describe baseline characteristics, disease progression and mortality in chronic thromboembolic pulmonary disease patients as a function of mean pulmonary artery pressure (mPAP) according to new and previous definitions of pulmonary hypertension.
Methods: All patients diagnosed with chronic thromboembolic pulmonary disease between January, 2015 and December, 2019 were dichotomized according to initial mPAP: ≤ 20 mmHg ('normal') vs 21-24 mmHg ('mildly-elevated'). Baseline features were compared between the groups, and pairwise analysis performed to determine changes in clinical endpoints at 1-year, excluding those who underwent pulmonary endarterectomy or did not attend follow-up.
Article Synopsis
- - The study analyzed genotype-phenotype associations in patients with T-BOX transcription factor 4-associated pulmonary arterial hypertension (PAH) by assessing variants and their effects on lung disease through a multicenter cohort of 137 patients.
- - Using a novel luciferase reporter assay, researchers examined 42 missense variants, finding that gain-of-function mutations were linked to older age at diagnosis and variants in specific domains led to earlier disease presentation and higher rates of interstitial lung disease.
- - The results indicated that T-BOX variants not only cause a loss of function but also show gain-of-function effects, impacting disease severity and patient outcomes, with T-BOX carriers exhibiting worse lung function and earlier diagnoses compared to those with other
Autoimmunity is believed to play a role in idiopathic pulmonary arterial hypertension (IPAH). It is not clear whether this is causative or a bystander of disease and if it carries any prognostic or treatment significance. To study autoimmunity in IPAH using a large cross-sectional cohort.
View Article and Find Full Text PDFHealth-related quality of life (HRQoL) scores assess symptom burden in pulmonary arterial hypertension (PAH) but data regarding their role in prognostication and risk stratification are limited. We assessed these relationships using the emPHasis-10 HRQoL measure.1745 patients with idiopathic PAH (IPAH), drug-induced PAH (DPAH), heritable PAH (HPAH) (collectively "(I/D/H)PAH"), or connective tissue disease-associated PAH (CTD-PAH), who had completed emPHasis-10 questionnaires at one of six UK referral centres between 2014 and 2017, were identified.
View Article and Find Full Text PDFBackground: BMP9, originating from the liver, and BMP10 are circulating BMPs that preserve vascular endothelial integrity. We assessed BMP9, BMP10 and soluble endoglin (sEng) levels and their relationships to liver disease severity and associated pulmonary vascular syndromes in a cohort of well-characterised liver disease patients.
Methods: Plasma samples from patients with liver disease (n = 83) and non-disease controls (n = 21) were assayed for BMP9, BMP10 and sEng.